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results brief

Optimizing Maternal, Newborn, and Child Health
Outcomes Through Use of Multidisciplinary
“IMPROVE” Teams in Lesotho: Costing component

HIV AND PMTCT IN LESOTHO

Attrition in HIV care and treatment for the general
population is around 20 percent; attrition for HIVpositive pregnant women in prevention of motherto-child transmission (PMTCT) programs is similar.4
The Lesotho government has attempted to address
issues in retention using various interventions;
however, the coordination of these at both the facility
and community level is somewhat convoluted. For
example, there is a lack of standardized job aids
or tools to assist in managing patients among
cadres at the facility level, to help ensure consistent
messaging and care coordination. Furthermore,
the role that village health workers (VHWs) play in

Despite its small size, Lesotho has the second
highest HIV prevalence globally. HIV prevalence
was 23.6 percent in 2018, approximately the same
rate which has been observed since 2005.1 Women
disproportionately share this burden in Lesotho; out
of the 330,000 adults living with HIV, 58 percent
were women. Additionally, new HIV infections among
young women aged 15–24 years were more than
double those among young men2 and account for
approximately one quarter of all new adult HIV
infections every year.3

KEY FINDINGS
● The total average unit cost for each of the five
services—antenatal care (ANC), family planning
(FP), prevention of mother-to-child-transmission
(PMTCT), postnatal care (PNC), and pediatric
antiretroviral therapy (ART)—was higher in
the intervention arm when compared to the
control arm of the study. The unit cost for ANC
services was $205 and $277 in the control
versus intervention arms, respectively. The cost
of FP was $81 in the control arm and $87 in
the intervention arm. The unit cost for PMTCT
services was $296 in the control arm versus
$311 in the intervention arm. The cost for PNC
services was $84 in the control arm and $97
in the intervention arm. The cost of pediatric
ART was $321 and $347 for the control and
intervention arms, respectively.
● The cost of the IMPROVE intervention is
substantially higher for ANC services (35%)
compared to current treatment protocol in
Lesotho. However, the cost for subsequent
services were only slightly higher in the
intervention arm compared to the control arm—

FP (8%), PMTCT (5%), PNC (15%), and pediatric
ART (8%).
● The cost of the IMPROVE intervention, especially
the integrated approach for FP, PMTCT, and
pediatric ART, is not prohibitive, and has the
potential to improve coordination of care at
relatively low cost to existing services.
● Scaling up the intervention would not require
a significant amount of financial support or
significant human resources.
● As this intervention builds primarily on an already
existing healthcare system and infrastructure,
there is potential to expand it beyond PMTCT care
models.
● The results from this analysis add to the current
body of evidence on health costing being collated
by the Global Health Cost Consortiuma and can
also be utilized for additional analysis (HIV, FP,
PMTCT, etc.) and impact modeling applications.

Accessed via GHCosting.org
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supporting new mothers in maternal, newborn, and
child health (MNCH)/PMTCT care is not clearly linked
to facility-based services. While support groups exist
for mothers, social and cultural stigma remains and
affects uptake of these services.

have historically dropped out. Additionally, it is
also expected that there will be broader benefits
of the intervention among both HIV-positive and
HIV-negative women and their infants, as their care
becomes more integrated and actively managed.

In response to these challenges, the Elizabeth
Glaser Pediatric AIDS Foundation (EGPAF) designed
the multidisciplinary “Integrated Management Team
to Improve Maternal-Child Outcomes (IMPROVE)”
intervention to improve patient-centered care
and to boost uptake of family planning (FP) and
MNCH services (specifically, antenatal care
[ANC] and postnatal care [PNC]) as well as to
improve adherence and retention for patients on
antiretroviral therapy (ART). This study builds on
the USAID-funded PMTCT service delivery program
already being implemented by EGPAF in Lesotho.
Rather than designing a suite of entirely new
services and delivery platforms, the intervention
focused on improving existing services and
strengthening the connection between facility and
community-based care through:

From a financial perspective, the cost of
implementation is expected to be low, as it leverages
the existing health care system and does not
introduce any particularly costly components. This
brief describes the approach and key quantitative
findings of the costing component of the IMPROVE
intervention from the service provider perspective.

1. The creation of multidisciplinary integrated
management teams, combining facility-based
MNCH providers, VHWs, and representatives
from community-based organizations
(mothers2mothers [m2m] and Lesotho Network
of AIDS Service Organizations [LENASO]), who
meet regularly to improve coordination of care
and follow-up for patients lost to follow-up.
2. Enhanced Positive Health, Dignity, and
Prevention (PHDP)-focused training and job aids
to improve care and counseling provided by
IMPROVE team members.
3. Increased community-based support via an
additional home visit one to two weeks following
the first ANC visit to reduce loss to follow-up
among new mothers.
Due to various factors, pregnant women have
struggled to remain on ART during pregnancy and
during the post-partum period. By strengthening
team-based care at the facility-level and providing
an additional home-based visit during the initial
post-partum period, the IMPROVE intervention
can help target these points in care where women

RESEARCH QUESTIONS
The aim of the costing component of this study
is to determine the cost of the arms—control
(current standard treatment protocol) relative to
the intervention (IMPROVE)—and to identify key cost
drivers for each. Specifically, the aim is to estimate:
1. The cost per person per year (i.e., unit cost) of
each of the five key IMPROVE services: general
MNCH, which includes both ANC and PNC; FP;
PMTCT; and pediatric ART services.
2. The major cost components/drivers of the five
key IMPROVE services.
Understanding these costs will provide evidence
for those considering the scale up or expansion of
the IMPROVE intervention. Evidence from these
costing analyses can also help inform policy
recommendations to improve existing PMTCT/MNCH
services.

METHODS
IMPROVE used a cluster randomized study design
with 12 facilities randomized to receive either
routine MNCH/PMTCT care based on current
treatment protocol plus the IMPROVE intervention,
or a control group, which offered routine care
based on current treatment protocol only. These
facilities were all based in Maseru district, which
includes both rural and urban settings, and reflects
a range of service delivery modes. A cohort of 1,004
women (614 HIV-negative and 390 HIV-positive)
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were enrolled in the study at their first ANC visit
and followed until the last set of study participants
recruited were at 12 months post-delivery. The effect
of IMPROVE was evaluated via primary outcomes,
including treatment retention, adherence, viral
suppression, and HIV retesting (perinatally and at 12
and 24 months postpartum), as well as via various
secondary outcomes measuring uptake of MNCH
services.
The cost evaluation of facility-based delivery of
IMPROVE services began in November 2018.
Data collection instruments were designed in
collaboration with EGPAF staff to collect data from
multiple sources including facility, district, and
national health staff and patient forms. After an
initial pilot-testing period, adjustments were made
to data collection forms to reflect availability of
aggregate patient service delivery and cost data.
These data were collected from interviews with staff
at the facility, district, and national levels of the
Ministry of Health and their implementing partners
(including EGPAF) by a team of Maseru-based
costing consultants. Data on service delivery—types
of services offered at the site, number of patients or
patient visits by service, and total number of patients
or patient visits—were collected from summary
registration forms and cross-referenced with MoH’s
District Health Information Software (DHIS2). The
cost data were categorized by the following cost
components:
1. Clinical staff costs: These are defined as the
estimated time facility-based clinical providers
reported spending with the average patient
through specific stages (registration, triage,
counseling and testing, consultation, adherence
counseling, pharmacy, etc.) during a visit by
type of service (ANC, FP, PMTCT, PNC, and
pediatric ART). The costs are then calculated
by multiplying the reported time spent by the
average salary of providers by cadre, the average
number of staff providing services at each
stage of care by staff cadre, and the estimated
number of visits per year for each type of
service.
2. Laboratory costs: These include the cost of
lab commodities (test kits, lab tests, etc.) and

the estimated time, reported by lab staff, spent
conducting lab tests (blood draw, running test,
interpreting test) for each type of patient by
service. It also includes the average cost of
transporting samples from facilities to testing
laboratories (based on national average sample
transportation costs). As with clinical staff costs,
lab staff costs are then calculated by multiplying
the reported time spent running each type of
test (HIV, dried-blood spot) by the average salary
of staff and the estimated number of tests per
patient per year for each type of service. Lab
testing occurs at either one of three of the 12
study facilities or at the National Reference
Laboratory. Costs were collected from all three
facilities, as well as from the National Reference
Laboratory. As such, the time spent by lab staff
and salary of staff cadres who performed lab
services were averaged across these three
sources and applied to each of the 12 facilities.
3. Support staff costs: These are defined as time
spent by facility-based staff who do not provide
direct clinical services to patients but whose
work supports these services at the facility (for
example, night guard, cleaner, accountant/
bookkeeper). The costs are then calculated for
each cadre by multiplying the reported time
spent by the average salary of each support
staff cadre based at that facility and the
estimated proportion of time spent supporting
each type of service reported by the same
facility. Where the support staff were unable to
provide an estimate of the time spent supporting
each type of service, costs were estimated by
multiplying the staff salary by the proportion of
patients or patient visits by service area. The
patient proportion by service area is calculated
by dividing the number of patients or patient
visits for each service area by the total number
of patients or patient visits for each facility,
respectively, depending on which of these two
sets of data is available.
4. Integrated multidisciplinary management
team costs: This is defined as the average
amount of time each facility’s multidisciplinary
team member spends in meetings to improve
coordination of care and follow-up for patients
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lost to follow-up. This cost is calculated by the
amount of reported time spent in meetings per
month multiplied by the average salary of each
team member and the number of meetings a
year (12). These costs are apportioned to each
of the five service areas for each facility using
the number of patients or patient visits divided
by the total number of patients or patient visits
for each facility, respectively, depending on
which of these two sets of data is available.
5. District health management team: This is
the cost of the average reported time spent by
the Maseru district health management staff
supervising and supporting each facility program
and the average time spent visiting/supervising
each facility per month multiplied by the number
of months in a year (12) and the average annual
salary of each cadre of the district health
management team. These district support teams
also include MOH as well as implementing
partner staff.
6. Drugs and commodities costs: This is
calculated as the average quantity of each drug,
medical commodity, and supply item used during
a patient visit for each type of service reported
by facility-based clinical providers multiplied
by that cost per item of that drug, medical
commodity, or supply. The cost of two key drugs
and commodities—ARVs and contraceptive
commoditiesa—were calculated using an average
weighted cost based on the number of patients
on each of the four major ARV regimens used
by patients across the 12 sites5 and the five
contraceptive methods reported in Lesotho’s
most recent DHS survey,6 respectively.
7. Operating costs: This is defined as the cost
of utilities (water, telephone, electricity, etc.),
transportation (per diem, mobile and emergency
vehicle maintenance, etc.), and maintenance
costs (building and equipment maintenance).
These costs are apportioned to each of the
service areas for each facility using the number
of patients or patient visits divided by the total
number of patients or patient visits for each
National Drug Service Organization-Central Store Price List
and UNFPA/Lesotho price list.
a

facility, respectively, depending on which of
these two sets of data is available.
8. Equipment costs: These are the cost of
medical equipment and furniture estimated by
amortizing the cost of each piece of equipment
used the year it was purchased, its lifespan/
replacement period, and whether or not it was
used for each of the types of services. Like
operating costs, these costs are apportioned to
each of the service areas for each facility using
the number of patients or patient visits divided
by the total number of patients or patient visits
for each facility, respectively, depending on
which of the two sets of data is available.
All financial and cost data were collected in local
currency (Maloti) and then converted to U.S. dollars
(USD) using the average exchange rate over the
study period (November 2017 to October 2019).b
All 12 facilities offered ANC, HCT, PMTCT, PNC, and
pediatric ART services. Only 5 of the 12 facilities
offered FP services—two in the control arm and three
in the intervention arm (including one hospital).
Some of the costs pertaining to the intervention
could not be separated from general program
costs, specifically pre-implementation costs for the
development of job aids, training at the site level
for use of these aids, and start-up costs of the
multidisciplinary team meetings, and thus were not
available for analysis. The incremental cost of the
additional home visit was also not available as it
was performed for all patients (including non-study
participants) and across all facilities (including nonstudy facilities); as such it could not be allocated to
either the control or intervention arm.
To compare between control and intervention facility
costs, data were averaged across the six facilities
in each of the two arms. Since FP services were
only offered in two control and three intervention
facilities, FP service costs were averaged for these
two groups of facilities for comparison. Lastly, the
International Monetary Fund, Representative Exchange rates
accessed via https://www.imf.org/external/np/fin/ert/GUI/
Pages/Report.aspx?CT=%27ZAF%27&EX=REP&P=
DateRange&Fr= 636051744000000000&To=
637079904000000000&CF= Compressed&CUF=Period&
DS=Ascending&DT=Blank
b
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percentage cost difference of each service area
was calculated by subtracting the total average unit
cost of each service in the control arm from the
total average unit cost of the corresponding service
in the intervention arm, the result of which is then
divided by the total average unit cost of that service
in the control arm and multiplied by 100 to convert
to percent.

RESULTS
The average cost per person per year for each of
the five service areas and the percentage difference
(intervention cost relative to control cost) by study
arm are shown in Table 1.
As anticipated, the estimated total average unit cost
was highest for PMTCT and pediatric ART patients,
in both arms. The total average unit cost for PMTCT
patients was $296 in the control arm versus $311
in the intervention arm, while the total average unit
cost for pediatric patients was $321 and $347 for
the control and intervention arms, respectively. The
total average unit cost for ANC services are $205

and $277 in the control versus intervention arms,
respectively. However, it is important to note that
when the $14.69 cost of counseling and testing
(including the cost of HIV test kits) are excluded from
ANC services, the cost falls to $190 and $263 in the
control and intervention study arms, respectively.
The total average unit cost for PNC services is
approximately $84 in the control arm and $97 in the
intervention arm. The total average cost per woman
per year for FP services in the control arm was $81
in the control arm and $87 in the intervention arm.
The total average unit cost for each of the services
provided in the intervention arm were relatively
higher than the total average unit cost in the control
arm. The results show that the percentage cost
difference for FP, PMTCT, and pediatric ART were
8 percent, 5 percent, and 8 percent, respectively.
The intervention cost of PNC was 15 percent higher
than the control cost, while ANC had the highest
percentage cost difference at 35 percent.
The cost per person by service area is further
disaggregated into eight cost categories, which are
displayed in Table 2.

Table 1 Cost per woman per year by service area and study arm (USD)
Control
USD

Intervention
USD

Cost difference (intervention
cost–control cost)
USD

Percentage difference of
intervention cost relative
to control cost
%

Antenatal care

205

277

72

35

Family planning

81

87

6

7

PMTCT

296

311

15

5

Postnatal care

84

97

13

15

Pediatric ART

321

347

26

8
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Table 2 Unit cost by service and by cost proportions—control and intervention arms
Control
Intervention
Service area/cost component
Cost (USD)
Cost (%)
Cost (USD)
Cost (%)
Antenatal care
Clinical staff costs
46.01
22
49.19
18
Laboratory costs
108.19
53
112.39
41
Support staff costs
0.03
0
0.02
0
Multidisciplinary team costs
NA
0
54.78
20
District health staff costs
0.02
0
0.02
0
Drugs and commodities
8.07
4
14.63
5
Operating costs
13.39
7
25.67
9
Equipment costs
29.32
14
20.51
7
Family planning
Clinical staff costs
46.37
58
37.28
43
Laboratory costs
—
0
—
0
Support staff costs
0.03
0
0.01
0
Multidisciplinary team costs
NA
0
22.58
26
District health staff costs
—
0
0.02
0
Drugs and commodities
33.82
42
26.82
31
Operating costs
0.14
0
0.19
0
Equipment costs
0.26
0
0.28
0
PMTCT
Clinical staff costs
89.26
30
95.66
30.8
Laboratory costs
75.79
26
80.54
25.9
Support staff costs
0.03
0
0.01
0.0
Multidisciplinary team costs
NA
0
5.28
2
District health staff costs
0.04
0
0.03
0
Drugs and commodities
117.07
39
115.84
37
Operating costs
5.33
2
8.24
2.7
Equipment costs
8.96
3
4.97
1.6
Postnatal care
Clinical staff costs
46.01
55
49.19
51
Laboratory costs
—
0
—
0
Support staff costs
0.02
0
0.01
0
Multidisciplinary team costs
NA
0
10.43
11
District health staff costs
0.02
0
0.01
0
Drugs and commodities
7.64
9
10.58
11
Operating costs
13.65
16
12.22
13
Equipment costs
16.69
20
14.54
15
Pediatric ART
Clinical staff costs
124.04
39
148.72
43
Laboratory costs
76.14
24
77.09
22
Support staff costs
0.02
0
0.01
0
Multidisciplinary team costs
NA
0
0.41
0
District health staff costs
0.02
0
0.01
0
Drugs and commodities
119.28
37
119.28
34
Operating costs
0.38
0
0.56
0
Equipment costs
0.77
0
0.51
0
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Although the average total cost of each of the
service areas was higher in the intervention arm
relative to the control arm, when disaggregated into
their respective cost components, those differences
showed wider variation within each study arm that
did not match the same pattern as the total average
cost. Additional analysis of the disaggregated cost
components showed that these variations were
primarily a result of three key input factors. These
are:
1. Variation in provider responses on average
time spent per patient per service area, the
average number of visits per patient per year
by service area, the average time spent per
patient per visit, and the quantity of drugs and
commodities used for each patient per visit. The
data collection strategy relied heavily on staff
responses, and even though all facilities noted
following standard treatment protocols for all
five service areas, these treatment protocols do
not stipulate standard time spent per patient
per visit. Equally important, the quantity of
certain drugs and commodities vary by patient
need while the number of visits per patient per
year are dependent on patient-specific factors
(availability, accessibility, and affordability).
2. The allocation key used in apportioning shared
costs. The proportion of patient or patient
visits by service area assumes that all patients
utilize facility resources equally regardless of
the type of service provided. In other words, a
patient who comes for ANC services receives
similar services as a patient who comes for FP,
PMTCT, PNC, and pediatric ART. While not the
most precise method for apportioning shared
costs, this method was the most efficient given
the study limitations. Additionally, the method
weights MNCH patients more, particularly ANC
patients, who represent the largest share of
patients—9 percent of patients in the control arm
and 10 percent of patients in the intervention
arm.
3. Financial records on operating and equipment
costs showed variation within each arm.
Hospitals reported higher operating costs, and
these costs were higher on average for facilities

in the intervention arm relative to the control
arm. Similarly, available records showed medical
equipment used in the control arm were slightly
newer (average purchase date May 2016) than
the intervention arm (average purchase date
February 2015). This means that on average the
estimated value of equipment used for patients
in the control arm was slightly higher than in the
intervention arm.
With these key variations in mind, the cost drivers
are discussed by service area below.

Antenatal care

Cost drivers for ANC services vary between
the control and intervention arms. The largest
contributor to costs in the control arm is laboratory
services, accounting for 53 percent of the total
average ANC cost, a major portion of which is
the result of the high cost of HIV, STI, and blood
grouping tests. The second largest share of ANC
service costs provided under the current guidelines
is clinical staff costs (22%) followed by equipment
costs (14%), operating costs (7%), and drugs and
commodities (4%). Similar to control facilities, lab
costs account for the largest share (41%) of ANC
services provided by IMPROVE intervention facilities.
However, this is followed by the cost of oversight
and support provided by the multidisciplinary team
(20%), then clinical staff cost (18%), operating costs
(9%), equipment costs (7%), and, lastly, the cost of
drugs and commodities (5%). The key contributing
factor to the difference between the study arms is
the inclusion of costs associated with the oversight
and support provided by the multidisciplinary team
at each intervention facility. Of the $72 (35%)
cost difference between intervention and control
facilities, an estimated $55 can be attributed to the
cost of the multidisciplinary team, representing a
substantial two-thirds of the cost difference between
intervention and control ANC services.

Family planning

When disaggregated into the eight cost components,
cost drivers for control and intervention facilities
mostly follow similar distribution patterns. For FP
services in the control arm, costs are split across
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clinical staff costs and the costs of drugs and
commodities, with clinical staff costs accounting
for the largest share (58%) while drugs and
commodities account for the remainder (42%). In the
intervention arm, FP services are split across three
cost components—clinical staff (43%), drugs and
commodities (31%), and the multidisciplinary team
(26%). In both arms, the allocated costs (support
staff, operating costs, equipment costs) account for
a minimal share in total costs, less than 1 percent.

PMTCT

The largest share of the unit cost of PMTCT
services is the cost of drugs and commodities,
estimated to be 39 percent of the average cost
of services at control facilities and 37 percent of
the total average cost at intervention facilities, per
woman per year. As expected, ARVs account for
the largest share of PMTCT costs at 36 percent
and 34 percent of the total average unit cost in
control and intervention facilities, respectively. After
drugs and commodities, the cost of clinical staff
time account for approximately 30 percent and 31
percent of total average PMTCT costs in control and
intervention facilities, respectively. Laboratory costs
account for the third largest share of costs (26%) of
PMTCT services in both the control and intervention
facilities. At this point, the cost distribution for both
control and interventions diverge. In the control arm,
the remainder of the share of cost of PMTCT services
are divided into equipment (3%) and operating costs
(2%). In the intervention arm, the remainder of the
share of PMTCT service costs are split by operating
(2.6%), multidisciplinary team (2%), and equipment
(1.6%) costs.

Postnatal care

In control facilities, clinical staff costs account for a
little more than half (55%) of the estimated average
unit cost of PNC, followed by equipment costs (20%),
operating costs (16%), and the cost of drugs and
commodities (9%). In intervention facilities, clinical
staff costs also account for a little more than half
(51%) of the share of the cost of PNC services,
followed by equipment (15%) and operating costs
(13%), with the remainder split evenly between
the cost of drugs and commodities (11%) and the

multidisciplinary team (11%). As with ANC cost, the
$11 cost of the multidisciplinary team represents
more than two-thirds of the $13 cost difference
between PNC services in intervention facilities
relative to control facilities.

Pediatric ART

The cost distribution of pediatric ART services follows
the same pattern for both control and intervention
facilities. Clinical staff costs represent the largest
share of pediatric ART service costs, accounting for
39 percent of total average cost in control facilities
and 43 percent in intervention facilities, per child
per year. In both study arms, the cost of drugs and
commodities account for the second largest share of
costs, accounting for 37 percent in control facilities
and 35 percent in intervention facilities. Laboratory
costs account for the remainder of the share of
total average pediatric ART services at 24 percent
in control facilities and 22 percent in intervention
facilities.

DISCUSSION
The cost of the IMPROVE intervention, especially the
integrated approach for FP, PMTCT, and pediatric
ART, is not prohibitive and has the potential to
improve coordination of care at relatively low cost
to existing services. More specifically, this relatively
low-cost difference suggests that the IMPROVE
intervention’s integrated approach does not require
substantial investments to provide integrated
services for HIV-positive women and their HIV
care. With a relatively low cost, and potential for
overall improvement in coordinated care, it is worth
exploring the expansion of the IMPROVE intervention
beyond PMTCT programming, and to adapt it to
additional health areas and care models.
As an entry point for the intervention, the
coordinating efforts of the multidisciplinary team
adds some costs to ANC services relative to the
other service areas. However, this is likely because
ANC is often where women needing additional
support are identified and providers likely spend
more time in the multidisciplinary groups discussing
individualized care plans, supplementary support,
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and/or additional home visits The multidisciplinary
team’s higher cost-share of ANC services relative
to the lower cost-share of subsequent services
(FP, PNC for HIV-negative women, PMTCT for HIVpositive women), suggests that the early investment
in ANC services reduces the need for additional
care coordination in PMTCT and other MNCH
services. In an already overburdened and resource
strained healthcare system, reducing the need
for this additional care management could free
up valuable financial and human resources to be
utilized elsewhere. The opportunity to repurpose
these resources, coupled with the low cost of the
intervention, suggests that the IMPROVE model can
have multiple beneficial effects upon the overall
healthcare system.

y In most cases, clinical and support staff were only
able to provide a best estimate of the amount of
time spent with patients in each type of service
rather than actual observed time. While it was
the most efficient data collection methodology for
the study, these estimates are likely subject to
reporting bias.

A key lesson from the IMPROVE intervention is
that there is a need to explore the possibility that
integration and coordination across other MNCHrelated programs (e.g., malaria, nutrition) at a key
service entry point like ANC may reduce the cost
of additional support services in the subsequent
service areas outlined above (FP, PNC, PMTCT, and
pediatric ART). Future studies will need a more
comprehensive approach to track patient resourceuse (while ensuring there are ethical safeguards
in place) to better understand and document how
investment at key service entry points relates to
future service utilization and, possibly, gain longterm efficiencies in service delivery.

y Data for one category of operating costs—external
services—were available for only one of the control
facilities and were estimated to be over $20,000
in one year. The inclusion of these data would
have skewed the average operations cost in the
control arm, and as such they were excluded from
the results.

LIMITATIONS
y The study was geographically limited to Maseru
district, which may not be representative of the
entire country.
y Several costs pertaining to the intervention were
not available: pre-implementation costs for the
development of job aids, training at the site level
for use of these aids, and the start-up cost of the
multidisciplinary team meetings. The incremental
cost of the additional home visit was also not
available, as it was performed for all patients
(including non-study participants) and across
all sites (including non-study facilities); as such
it could not be allocated to either the control or
intervention arm.

y National averages had to be used as proxy for
some cost data (e.g., government lab salaries,
laboratory sample transportation). The number
of PNC patients or patient visits could not be
triangulated with DHIS2 or other sources to
verify accuracy. This has implications for the
methodology used to apportion costs by each
service area’s proportion of number of patients or
patient clinic visits and overall cost estimates.

CONCLUSIONS
The IMPROVE intervention resulted in a better
understanding of inefficiencies at the service
delivery level in Lesotho and helped to spark
conversations around the importance of patientcentered care and efficient, low-cost methods of
improving both facility- and community-based care
models. The intervention proved to have a minimal
additional cost and is potentially scalable beyond
the Maseru district in Lesotho, and beyond PMTCT/
MNCH services. The collection of cost data also
identified areas in which there is limited visibility into
cost and operational data (see limitations above),
which can potentially help inform the design of
future cost studies in similar settings. Cost data from
IMPROVE will continue to be utilized beyond this final
analysis, and will contribute to a growing database of
cost data via the Global Health Costing Consortium,
helping to inform future planning methods, models,
and analysis focused on HIV testing, PMTCT, MNCH,
and FP.

Project SOAR Results Brief │ 9

REFERENCES
1. Avert. 2019. HIV and AIDS in Lesotho. Retrieved
3 October 2019 from https://www.avert.org/
professionals/hiv-around-world/sub-saharanafrica/lesotho
2. UNAIDS. “AIDSinfo.” (Accessed October 2019)
https://aidsinfo.unaids.org/
3. UNAIDS. 2018. “Lesotho HIV and health
situation room brings innovation to country’s
AIDS response.” Retrieved December 2,
2019, from https://www.unaids.org/en/
resources/presscentre/featurestories/2018/
may/20180509_Lesotho_situation_room.
4. Elizabeth Glaser Pediatric AIDS Foundation
(EGPAF), Lesotho country program data. Project
SOAR, IMPROVE Protocol.
5. Elizabeth Glaser Pediatric AIDS Foundation
(EGPAF), Lesotho country program data.
6. Ministry of Health [Lesotho] and ICF International.
2016. Lesotho Demographic and Health Survey
2014. Maseru, Lesotho: Ministry of Health and
ICF International. https://dhsprogram.com/pubs/
pdf/FR309/FR309.pdf

Suggested citation: Adesina, Adebiyi, Rachael Linder, and Lori
Bollinger. 2021. “Optimizing maternal, newborn, and child
health outcomes through use of multidisciplinary ‘IMPROVE’
teams in Lesotho: Costing component,” Project SOAR Results
Brief. Washington, DC: Population Council.

Project SOAR is a six-year+ (September 2014–January 2021) cooperative
agreement funded by the U. S. President’s Emergency Plan for AIDS Relief
(PEPFAR) and the U. S. Agency for International Development (Agreement No.
AID-OAA-A-14-00060). The contents of this brief are the sole responsibility of
Project SOAR and Population Council and do not necessarily reflect the views
of PEPFAR, USAID, or the United States Government.

Project SOAR/Population Council
4301 Connecticut Avenue, NW, Suite 280
Washington, DC 20008
Tel: +1 202 237 9400
e-mail: ProjectSOAR@popcouncil.org
projsoar.org

Population Council leads the Project SOAR consortium in collaboration with
Avenir Health, Elizabeth Glaser Pediatric AIDS Foundation, the Johns Hopkins
University, Palladium, and The University of North Carolina at Chapel Hill.

©Population Council, January 2021

